Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Emerge Weight Loss vs Midi Health

Emerge Weight Loss
Graded #448

Lower grade

vs+1.2999999999999972
Midi Health
Graded #414

Higher grade

The verdict

Midi Health takes it — 56.4/100 to 55.1/100, but only just.

Midi Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Midi Health is a nationwide 50-state menopause and perimenopause telehealth platform. Emerge Weight Loss is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMidi Health +9
36
45
Dose & formulationEmerge Weight Loss +2
42
40
Clinical oversightEmerge Weight Loss +6
84
78
Labs & monitoringEmerge Weight Loss +2
54
52
FulfillmentMidi Health +8
70
78
Contract termsEven
55
55
Emerge Weight Loss · left barMidi Health · right bar

The numbers

MetricEmerge Weight LossMidi Health
WeighScore55.1/10056.4/100
GradeCC
Scorecard rank#448#414
SemaglutideNot disclosedNot disclosed
Tirzepatide$287/mo (2.5 mg dose, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Emerge Weight Loss

Graded #448 · C

Strengths

  • Tirzepatide-focused (largest effect-size compounded GLP-1)
  • Wide dose range available
  • Physician-supervised telemedicine model

Where it loses points

  • Semaglutide is available only on request — the site and default plans are tirzepatide-only
  • Less brand recognition than Henry Meds, Mochi, or SkinnyRx
Midi Health

Graded #414 · C

Strengths

  • Available in all 50 states
  • Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
  • Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
  • Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)

Where it loses points

  • Does not accept Medicare, Medicaid, or Medi-Cal
  • GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
  • Menopause-focused — not the right fit for men or younger women whose main goal is weight loss

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard